Biomarker response on exposure to sunitinib and its primary metabolite (SU12662) in metastatic colorectal cancer patients.

Kanefendt, F., Lindauer, A., Kinzig, M., Strumberg, D., Scheulen, M.E., Mross, K., Fischer, R., Moritz, B., Sörgel, F., Jaehde, U., 2011.

Int J Clin Pharmacol Ther 49, 88–90.

Studie: CESAR-C-II-005; Indikation: Kolorektalkarzinom; Jahr: 2011; Veranstaltung: -; Journal: International Journal of Clinical Pharmacology and Therapeutics

iOMEDICO AG
Hanferstraße 28
79108 Freiburg

Tel: 0761 - 15 242 0
E-Mail: info@iomedico.com